Cargando…
High levels of SARS-CoV-2–specific T cells with restricted functionality in severe courses of COVID-19
BACKGROUND: Patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) differ in the severity of disease. We hypothesized that characteristics of SARS-CoV-2–specific immunity correlate with disease severity. METHODS: In this study, SARS-CoV-2–specific T cells and antibodies...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605520/ https://www.ncbi.nlm.nih.gov/pubmed/32937615 http://dx.doi.org/10.1172/jci.insight.142167 |
_version_ | 1783604317956079616 |
---|---|
author | Schub, David Klemis, Verena Schneitler, Sophie Mihm, Janine Lepper, Philipp M. Wilkens, Heinrike Bals, Robert Eichler, Hermann Gärtner, Barbara C. Becker, Sören L. Sester, Urban Sester, Martina Schmidt, Tina |
author_facet | Schub, David Klemis, Verena Schneitler, Sophie Mihm, Janine Lepper, Philipp M. Wilkens, Heinrike Bals, Robert Eichler, Hermann Gärtner, Barbara C. Becker, Sören L. Sester, Urban Sester, Martina Schmidt, Tina |
author_sort | Schub, David |
collection | PubMed |
description | BACKGROUND: Patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) differ in the severity of disease. We hypothesized that characteristics of SARS-CoV-2–specific immunity correlate with disease severity. METHODS: In this study, SARS-CoV-2–specific T cells and antibodies were characterized in uninfected controls and patients with different coronavirus disease 2019 (COVID-19) disease severity. SARS-CoV-2–specific T cells were flow cytometrically quantified after stimulation with SARS-CoV-2 peptide pools and analyzed for expression of cytokines (IFN-γ, IL-2, and TNF-α) and markers for activation, proliferation, and functional anergy. SARS-CoV-2–specific IgG and IgA antibodies were quantified using ELISA. Moreover, global characteristics of lymphocyte subpopulations were compared between patient groups and uninfected controls. RESULTS: Despite severe lymphopenia affecting all major lymphocyte subpopulations, patients with severe disease mounted significantly higher levels of SARS-CoV-2–specific T cells as compared with convalescent individuals. SARS-CoV-2–specific CD4(+) T cells dominated over CD8(+) T cells and closely correlated with the number of plasmablasts and SARS-CoV-2–specific IgA and IgG levels. Unlike in convalescent patients, SARS-CoV-2–specific T cells in patients with severe disease showed marked alterations in phenotypical and functional properties, which also extended to CD4(+) and CD8(+) T cells in general. CONCLUSION: Given the strong induction of specific immunity to control viral replication in patients with severe disease, the functionally altered characteristics may result from the need for contraction of specific and general immunity to counteract excessive immunopathology in the lung. FUNDING: The study was supported by institutional funds to MS and in part by grants of Saarland University, the State of Saarland, and the Rolf M. Schwiete Stiftung. |
format | Online Article Text |
id | pubmed-7605520 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Society for Clinical Investigation |
record_format | MEDLINE/PubMed |
spelling | pubmed-76055202020-11-04 High levels of SARS-CoV-2–specific T cells with restricted functionality in severe courses of COVID-19 Schub, David Klemis, Verena Schneitler, Sophie Mihm, Janine Lepper, Philipp M. Wilkens, Heinrike Bals, Robert Eichler, Hermann Gärtner, Barbara C. Becker, Sören L. Sester, Urban Sester, Martina Schmidt, Tina JCI Insight Clinical Medicine BACKGROUND: Patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) differ in the severity of disease. We hypothesized that characteristics of SARS-CoV-2–specific immunity correlate with disease severity. METHODS: In this study, SARS-CoV-2–specific T cells and antibodies were characterized in uninfected controls and patients with different coronavirus disease 2019 (COVID-19) disease severity. SARS-CoV-2–specific T cells were flow cytometrically quantified after stimulation with SARS-CoV-2 peptide pools and analyzed for expression of cytokines (IFN-γ, IL-2, and TNF-α) and markers for activation, proliferation, and functional anergy. SARS-CoV-2–specific IgG and IgA antibodies were quantified using ELISA. Moreover, global characteristics of lymphocyte subpopulations were compared between patient groups and uninfected controls. RESULTS: Despite severe lymphopenia affecting all major lymphocyte subpopulations, patients with severe disease mounted significantly higher levels of SARS-CoV-2–specific T cells as compared with convalescent individuals. SARS-CoV-2–specific CD4(+) T cells dominated over CD8(+) T cells and closely correlated with the number of plasmablasts and SARS-CoV-2–specific IgA and IgG levels. Unlike in convalescent patients, SARS-CoV-2–specific T cells in patients with severe disease showed marked alterations in phenotypical and functional properties, which also extended to CD4(+) and CD8(+) T cells in general. CONCLUSION: Given the strong induction of specific immunity to control viral replication in patients with severe disease, the functionally altered characteristics may result from the need for contraction of specific and general immunity to counteract excessive immunopathology in the lung. FUNDING: The study was supported by institutional funds to MS and in part by grants of Saarland University, the State of Saarland, and the Rolf M. Schwiete Stiftung. American Society for Clinical Investigation 2020-10-15 /pmc/articles/PMC7605520/ /pubmed/32937615 http://dx.doi.org/10.1172/jci.insight.142167 Text en © 2020 Schub et al. http://creativecommons.org/licenses/by/4.0/ This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Medicine Schub, David Klemis, Verena Schneitler, Sophie Mihm, Janine Lepper, Philipp M. Wilkens, Heinrike Bals, Robert Eichler, Hermann Gärtner, Barbara C. Becker, Sören L. Sester, Urban Sester, Martina Schmidt, Tina High levels of SARS-CoV-2–specific T cells with restricted functionality in severe courses of COVID-19 |
title | High levels of SARS-CoV-2–specific T cells with restricted functionality in severe courses of COVID-19 |
title_full | High levels of SARS-CoV-2–specific T cells with restricted functionality in severe courses of COVID-19 |
title_fullStr | High levels of SARS-CoV-2–specific T cells with restricted functionality in severe courses of COVID-19 |
title_full_unstemmed | High levels of SARS-CoV-2–specific T cells with restricted functionality in severe courses of COVID-19 |
title_short | High levels of SARS-CoV-2–specific T cells with restricted functionality in severe courses of COVID-19 |
title_sort | high levels of sars-cov-2–specific t cells with restricted functionality in severe courses of covid-19 |
topic | Clinical Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605520/ https://www.ncbi.nlm.nih.gov/pubmed/32937615 http://dx.doi.org/10.1172/jci.insight.142167 |
work_keys_str_mv | AT schubdavid highlevelsofsarscov2specifictcellswithrestrictedfunctionalityinseverecoursesofcovid19 AT klemisverena highlevelsofsarscov2specifictcellswithrestrictedfunctionalityinseverecoursesofcovid19 AT schneitlersophie highlevelsofsarscov2specifictcellswithrestrictedfunctionalityinseverecoursesofcovid19 AT mihmjanine highlevelsofsarscov2specifictcellswithrestrictedfunctionalityinseverecoursesofcovid19 AT lepperphilippm highlevelsofsarscov2specifictcellswithrestrictedfunctionalityinseverecoursesofcovid19 AT wilkensheinrike highlevelsofsarscov2specifictcellswithrestrictedfunctionalityinseverecoursesofcovid19 AT balsrobert highlevelsofsarscov2specifictcellswithrestrictedfunctionalityinseverecoursesofcovid19 AT eichlerhermann highlevelsofsarscov2specifictcellswithrestrictedfunctionalityinseverecoursesofcovid19 AT gartnerbarbarac highlevelsofsarscov2specifictcellswithrestrictedfunctionalityinseverecoursesofcovid19 AT beckersorenl highlevelsofsarscov2specifictcellswithrestrictedfunctionalityinseverecoursesofcovid19 AT sesterurban highlevelsofsarscov2specifictcellswithrestrictedfunctionalityinseverecoursesofcovid19 AT sestermartina highlevelsofsarscov2specifictcellswithrestrictedfunctionalityinseverecoursesofcovid19 AT schmidttina highlevelsofsarscov2specifictcellswithrestrictedfunctionalityinseverecoursesofcovid19 |